Ipamorelin reduced steroid-induced nitrogen wasting 20% and neutralised N-balance in rats
Background
Steroid-induced catabolism is a well-recognised clinical liability of long-term glucocorticoid therapy, driving protein breakdown, muscle wasting, and negative nitrogen balance across multiple organ systems. The liver is central to this process, upregulating the urea cycle to dispose of excess amino-nitrogen liberated by accelerated proteolysis. Growth hormone (GH) is known to attenuate these catabolic side effects by modulating alpha-amino-nitrogen metabolism, but direct GH administration carries limitations. Ipamorelin is a synthetic peptide GH secretagogue that stimulates endogenous GH release, raising the question of whether its downstream metabolic effects can replicate direct GH administration in a catabolic setting — a gap this study addresses.
Study Design
Five groups of male rats were assigned: (1) free-fed controls, (2) pair-fed controls, (3) prednisolone 4 mg × kg⁻¹ × day⁻¹, (4) prednisolone + GH 1 mg × kg⁻¹ × day⁻¹, and (5) prednisolone + Ipamorelin 0.5 mg × kg⁻¹ × day⁻¹. Treatment continued for seven days. Primary endpoints were hepatic capacity of urea-N synthesis (CUNS), liver mRNA expression of urea cycle enzymes assessed by qPCR-based methods, whole-body N-balance, and N-contents of various organs.
Results
Prednisolone versus pair-fed controls significantly increased CUNS (p<0.01), upregulated urea cycle gene expression (p<0.01), decreased N-balance (p<0.01), and reduced organ N-contents (p<0.05), confirming robust steroid-induced catabolism. Co-administration of GH reduced CUNS by 33% (p<0.01) versus prednisolone alone, fully normalised urea cycle gene expression, improved N-balance 2.5-fold, and normalised or improved organ N-contents across measured tissues.
Ipamorelin reduced
CUNSby 20% (p<0.05), decreasedurea cycleenzyme expression, neutralised N-balance to near-zero, and normalised or improved organ N-contents — all compared to prednisolone-only animals.
Both interventions opposed the prednisolone-driven catabolic signature, though GH achieved numerically larger reductions in CUNS (33% vs 20%) and a greater improvement in N-balance (2.5-fold vs neutralisation), indicating dose-dependent or mechanism-dependent differences at the doses tested.
Key Findings
- Prednisolone increased hepatic CUNS and urea cycle gene expression vs pair-fed controls (p<0.01)
- GH co-treatment reduced CUNS by 33% (p<0.01) and improved N-balance 2.5-fold vs prednisolone alone
- Ipamorelin reduced CUNS by 20% (p<0.05) and neutralised N-balance vs prednisolone alone
- Both GH and Ipamorelin normalised or improved organ N-contents depleted by prednisolone
- GH was more efficacious than Ipamorelin at the doses tested across all nitrogen endpoints
Why It Matters
Ipamorelin demonstrates functional GH-pathway metabolic activity in a physiologically relevant catabolic model, supporting its potential utility for mitigating steroid-induced tissue wasting rather than merely stimulating GH pulses. For clinicians managing patients on chronic glucocorticoid therapy, this signals that a GH secretagogue could offer a less invasive route to hepatic and systemic nitrogen preservation than exogenous GH injections. For practitioners considering peptide protocols, the dose ratio matters: Ipamorelin at 0.5 mg × kg⁻¹ × day⁻¹ was less efficient than GH at 1 mg × kg⁻¹ × day⁻¹, suggesting that dose optimisation or combination approaches may be needed to match direct GH efficacy. Translational distance remains significant — this is a 7-day rat model, and human dosing, long-term safety, and clinical endpoint validation have not been established.
